Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants
Michael P Douglas1, Grace A Lin2,3,4, Julia R Trosman2,5
1UCSF Center for Translational and Policy Research On Personalized Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California San Francisco, 490 Illinois Street, 3rd Floor, Box 0613, San Francisco, CA, 94143, USA. Michael.Douglas@ucsf.edu.
Insights
Financial assistance programs reduce hereditary cancer panel (HCP) testing costs for Latinx individuals. However, challenges remain regarding program sustainability, out-of-pocket expenses, and cascade testing access for families.
Area of Science:
- Genetics and Genomics
- Public Health
- Health Disparities
Background:
- Hereditary breast and ovarian cancers (HBOCs) disproportionately affect the Latinx population.
- Multi-gene hereditary cancer panels (HCPs) are recommended for risk assessment.
- Limited understanding exists regarding financial barriers to HCP testing in the Latinx community.
Purpose of the Study:
- To identify challenges and propose solutions for facilitating HCP testing in the Latinx population.
- To explore the impact of payer reimbursement and out-of-pocket costs on HCP utilization.
Main Methods:
- Conducted semi-structured interviews with healthcare providers (genetic counselors, oncologists, nurse practitioners) at safety-net institutions.
- Utilized deductive thematic analysis to identify key themes related to HCP testing barriers and solutions.
- Focused on providers serving the Latinx population in the San Francisco Bay Area.
Main Results:
- Laboratory patient assistance programs significantly reduce upfront financial barriers to HCP testing.
- Potential challenges include the long-term sustainability of low-cost testing, patient out-of-pocket expenses, and access to cascade testing for relatives.
- Pathogenic variants specific to the Latinx population require consideration in panel inclusivity.
Conclusions:
- While financial assistance mitigates some barriers, other factors impede equitable HCP testing access for Latinx individuals.
- Addressing sustainability of assistance programs, out-of-pocket costs, and cascade testing is crucial.
- Ensuring comprehensive testing panels that include Latinx-specific variants is essential for improving care.
Abstract:
Hereditary breast and ovarian cancers (HBOCs) are common among the Latinx population, and risk testing is recommended using multi-gene hereditary cancer panels (HCPs). However, little is known about how payer reimbursement and out-of-pocket expenses impact provider ordering of HCP in the Latinx population. Our objective is to describe key challenges and possible solutions for HCP testing in the Latinx population. As part of a larger study, we conducted semi-structured interviews with key provider informants (genetic counselors, oncologist, nurse practitioner) from safety-net institutions in the San Francisco Bay Area. We used a deductive thematic analysis approach to summarize themes around challenges and possible solutions to facilitating HCP testing in Latinx patients. We found few financial barriers for HCP testing for the Latinx population due to laboratory patient assistance programs that cover testing at low or no cost to patients. However, we found potential challenges related to the sustainability of low-cost testing and out-of-pocket expenses for patients, access to cascade testing for family members, and pathogenic variants specific to Latinx. Providers questioned whether current laboratory payment programs that decrease barriers to testing are sustainable and suggested solutions for accessing cascade testing and ensuring variants specific to the Latinx population were included in testing. The use of laboratories with payment assistance programs reduces barriers to HCP testing among the US population; however, other barriers are present that may impact testing use in the Latinx population and must be addressed to ensure equitable access to HCP testing for this population.
More Related Videos
Related Concept Videos
Cancer Prevention
Some...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...


